Press Releases 2012
- January 31, 2012
Takeda’s Annual Report 2011 and CSR Data Book 2011 Receive Special Prize in Sustainability Reporting Award - January 27, 2012
Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan - January 24, 2012
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
– Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration –
– Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy – - January 18, 2012
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth - January 18, 2012
New Drug Application Approval for AZILVA® in Japan, a Treatment of Hypertension - January 10, 2012
European Commission Adopts European Medicines Agency’s Opinion Confirming Pioglitazone-Containing Medicines Remain a Valid Treatment Option for Appropriate Type 2 Diabetes Patients
European Commission review is now concluded following the adoption of the CHMP Opinion made in October 2011 - January 6, 2012
Establishment of Joint Research Chair by Takeda and Osaka University
Development of platform for practical application and commercialization of nano-particle vaccines